NuCana plc - American Depositary Share (NCNA): Price and Financial Metrics
NCNA Price/Volume Stats
| Current price | $4.00 | 52-week high | $23.75 |
| Prev. close | $3.99 | 52-week low | $3.40 |
| Day low | $3.82 | Volume | 37,200 |
| Day high | $4.13 | Avg. volume | 59,275 |
| 50-day MA | $7.18 | Dividend yield | N/A |
| 200-day MA | $11.67 | Market Cap | 8.37M |
NCNA Stock Price Chart Interactive Chart >
NuCana plc - American Depositary Share (NCNA) Company Bio
NuCana plc develops anti-cancer medicines for ovarian, biliary, pancreatic, colorectal, haematology, oncology, and breast cancers. NuCana produces oncology medicines using a proprietary technology platform for cancer patients. The company was incorporated in 1997 and is based in Edinburgh, the United Kingdom.
Latest NCNA News From Around the Web
Below are the latest news stories about NUCANA PLC that investors may wish to consider to help them evaluate NCNA as an investment opportunity.
NuCana Reports Third Quarter 2023 Financial Results and Provides Business UpdateAnnounced Encouraging Updates from NUC-3373 and NUC-7738 Demonstrating Promising Efficacy and Safety Data Pipeline Continues to Advance with Data Updates Expected for all Programs in 2024 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, Nov. 16, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 30, 2023 and provided an update on its broad clinical development program with its transformative ProTi |
NuCana Announces Listing Transfer to Nasdaq Capital MarketEDINBURGH, United Kingdom, Nov. 10, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced today that it has received approval from Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its American Depositary Shares (“ADSs”) from the Nasdaq Global Select Market to the Nasdaq Capital Market. This transfer became effective at the opening of business on November 9, 2023. The Nasdaq Capital Market is a continuous trading |
NuCana to Present at the Jefferies London Healthcare ConferenceEDINBURGH, United Kingdom, Nov. 08, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies London Healthcare Conference. Event: Jefferies London Healthcare ConferenceDate: Tuesday, November 14, 2023Time: 8:00 AM GMTLocation: London, UK The presentation will be webcast live and available for replay under “Events & Presentations” in the Investo |
NuCana to Participate in the Truist Securities 2023 BioPharma SymposiumEDINBURGH, United Kingdom, Nov. 01, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one-on-one meetings at the Truist Securities 2023 BioPharma Symposium. Event: Truist Securities 2023 BioPharma SymposiumDate: November 8-9, 2023Location: New York, NY About NuCanaNuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients wit |
NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023Data from the NuTide:701 Study Indicate NUC-7738 May Potentiate the Activity of Anti-PD-1 Agents in Patients who were Refractory to or Progressed on Prior Immunotherapy, including Anti-PD-1 Therapy Several Patients Achieved Reductions in Tumor Volume and Prolonged Time on Treatment BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced a presentation on the ongoing NuTide:701 study of NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer T |
NCNA Price Returns
| 1-mo | -47.39% |
| 3-mo | -45.04% |
| 6-mo | -70.37% |
| 1-year | -82.80% |
| 3-year | -96.31% |
| 5-year | -98.75% |
| YTD | -45.91% |
| 2023 | -55.18% |
| 2022 | -72.27% |
| 2021 | -46.99% |
| 2020 | -26.39% |
| 2019 | -57.93% |
Loading social stream, please wait...